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Abstract We have recently reported on the development
of a biomimetic vein model to measure the performance of
sclerosing foams. In this study we employed the model to
compare the commercially-available Varithena (polido-
canol injectable foam) 1 % varicose vein treatment (re-
ferred to as polidocanol endovenous microfoam, or PEM)
with physician compounded foams (PCFs) made using
different foam generation methods (Double Syringe Sys-
tem and Tessari methods) and different foam formulations
[liquid to gas ratios of 1:3 or 1:7; gas mixtures composed of
100 % CO2, various CO2:O2 mixtures and room air (RA)].
PCFs produced using the DSS method had longer dwell
times (DTs) (range 0.54–2.21 s/cm in the 4 mm diameter
vein model) than those of the corresponding PCFs pro-
duced by the Tessari technique (range 0.29–0.94 s/cm).
PEM had the longest DT indicating the best cohesive
stability of any of the foams produced (2.92 s/cm). Other
biomimetic model variables investigated included effect of
vessel size, delayed injection and rate of plug formation
(injection speed). When comparing the 4 and 10 mm vessel
diameters, the DTs seen in the 10 mm vessel were higher
than those observed for the 4 mm vessel, as the vein angle
had been reduced to 5 to allow for foam plug formation.
PCF foam performance was in the order RA[CO2:O2
(35:65) % CO2:O2 (65:35)[CO2; PEM had a longer DT
than all PCFs (22.10 s/cm) except that for RA made by
DSS which was similar but more variable. The effect of
delayed injection was also investigated and the DT for
PEM remained the longest of all foams with the lowest
percentage deviation with respect to the mean values,
indicating a consistent foam performance. When consid-
ering rate of plug formation, PEM consistently produced
the longest DTs and this was possible even at low plug
expansion rates (mean 29.5 mm/s, minimum 20.9 mm/s).
The developed vein model has therefore demonstrated that
PEM consistently displays higher foam stability and
cohesiveness when compared to PCFs, over a range of
clinically-relevant operational variables.
1 Introduction
Varicose veins are a very common disease with symp-
tomatology that can significantly impact on a patient’s
Quality of Life (QoL) and—if left untreated—can cause
long-term injury to the skin, resulting in discolouration,
inflammation, and ultimately ulceration [1]. Vein vari-
cosities are related to congential or acquired abnormalities
of the deep venous system and venous valves, or vein wall
weakness [2]. Although life-threatening complications are
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rare, there is a considerable social and economic impact of
vein disease [3].
Several methods have been developed to treat varicose
veins, including radiofrequency and laser ablation, venous
stripping, surgery and sclerotherapy [4]. Sclerotherapy is
the least invasive method, and involves the intra-venous
injection of a liquid sclerosing agent (i.e., sodium
tetradecyl sulphate or polidocanol) to disrupt the endothe-
lial lining of the vein and ultimately lead to vessel sclerosis
[5]. However, the use of liquid sclerotherapy is confined to
smaller veins (i.e., B3 mm in diameter) [6], as the liquid
sclerosant is diluted and deactivated rapidly by blood [7].
In order to overcome this limitation, foamed sclerosants
have been introduced, which displace rather than mix with
blood, leading to greater contact time with the vein
endothelium [8]. Foamed sclerosants are usually produced
manually by the clinician, referred to as physician com-
pounded foams (PCFs). The two major techniques of PCF
production are (i) the double syringe system (DSS) method
[9], and (ii) the Tessari method [10]. In these techniques a
gaseous and a liquid phase are manually mixed by con-
necting two syringes together using a Combydin adapter
(DSS) or a three-way tap (Tessari). PCF created using
room air (RA) has been widely used, although the nitrogen
(N2) content that contributes to its stability [11, 12] also
increases the risk of gas embolism, with chest tightness
being reported as well as neurological symptoms [13]. This
has prompted investigation into foams made using clinical
grade carbon dioxide (CO2), or CO2 and oxygen (O2)
mixtures [14–16]. CO2 has greater solubility in blood [17],
which means the risk of gas embolism is reduced. These
foams are less stable [11], however, and are therefore less
efficient at displacing blood [12]. With the aim of
improving foam stability and production consistency,
automated systems have been recently proposed as an
alternative to manual techniques [6, 12, 18, 19]. Among
these, Polidocanol Endovenous Microfoam [PEM from
herein, manufactured by Provensis Ltd and cleared in the
USA under the name Varithena (polidocanol
injectable foam) 1 %] is a proprietary, low nitrogen,
CO2:O2 (35:65) pharmaceutical-grade polidocanol micro-
foam delivered from a proprietary canister system.
Despite sclerosing foams having been used in the clin-
ical environment [20], a limited amount of work has been
conducted to physically characterise foam properties
in vitro, particularly under clinically relevant experimental
conditions. A typical characterisation of foam properties
involves the measurement of bubble size, bubble size dis-
tribution, and foam half time (FHT, defined as the time
taken for the foam volume to decrease by a factor of two)
[21, 22]. However, these parameters are not sufficient to
fully characterise the behaviour of sclerosing foams in a
clinically relevant scenario. This will depend on the
interplay between (i) gravitational effects (i.e., further
depending on patient’s leg elevation), (ii) physical prop-
erties of the gaseous and liquid phases constituting the
foam, (iii) physical properties of the surrounding fluid
medium, (iv) bubbles size and size distribution, and
(v) clinical factors, such as time delay between foam pro-
duction and injection, and foam injection rate.
In our previous study we reported on the development of
a novel biomimetic model to experimentally measure the
interrelated properties of foam-induced liquid displacement
and foam cohesiveness [12]. By coupling the model with a
computational-based image analysis software, we revealed
the dynamics of foam plug degradation in a phantom vein
[12]. Importantly, we introduced a novel parameter
[Degradation rate (DR)] to quantify and compare the
cohesiveness of sclerosing foams [12]. In this study, we
employed the developed model to compare the cohesive-
ness of polidocanol-based PCFs and PEM, and evaluate the
effect of clinically-relevant parameters on foam cohesive-
ness. These include (i) the diameter of the target vessel, (ii)
foam production technique (PCF vs. PEM), (iii) type of
gaseous phase, (iv) foam density [i.e., liquid:gas ratio
(LGR)], (v) time delay between foam production and
injection and (vi) foam plug formation rate (injection
speed).
Results from this study may provide valuable informa-
tion to clinicians regarding the choice of the optimal
clinical practice to achieve the desired foam cohesiveness
and therapeutic effectiveness.
2 Materials and methods
2.1 Vein model set-up
The biomimetic vein model has been described in our
previous study [12]. It consists of a segment of polyte-
trafluoroethylene (PTFE) tubing (Thermo Scientific Inc.,
USA) positioned in a bespoke platform, which inclination
angle (a) could be adjusted and measured by a digital
liquid–crystal display (LCD) inclinometer (RS Compo-
nents Ltd., UK) (Fig. 1). 4 and 10 mm inner diameter (ID)
tubing were employed in the present investigation, in order
to simulate both small and large varicosities [2]. a was set
to 25 and 5 for the 4 and 10 mm ID tubing, respectively.
Fluids and foams were injected into the model via a three-
way stopcock (Baxter, USA).
Videos of foam plug expansion and degradation were
captured by means of a 1412 9 1059 pixels 9 pixels high
speed charge-coupled device (CCD) camera (Lumix,
Panasonic Corporation, Japan), with interframe time
interval of 30 ms. The camera was positioned on a metal
258 Page 2 of 10 J Mater Sci: Mater Med (2015) 26:258
123
stand, which height could be adjusted in order to control
the positioning of the field of view.
2.2 Experimental protocols
2.2.1 Foam production
Physician compounded foams (PCFs) Polidocanol was
employed as a foaming agent throughout these studies (see
Fig. 2 for its chemical structure) and was supplied by
Croda (Goole, UK) as a white waxy solid with a purity of
C99.0 %, as determined by gas chromatography. It has a
low reported critical micelle concentration of 0.002 % in
water or saline [23].
Foams were produced by mixing controlled volumes of
the aqueous buffered polidocanol solution and a gas or gas
mixture. A polidocanol concentration of 1 % (v/v in buf-
fered saline) was chosen, as clinical studies in varicose
vein treatment comparing efficacy of 1 and 3 % polido-
canol found no statistically significant difference between
the two concentrations [24, 25], and this allowed for direct
comparison of PCFs with PEM which is made from 1 %
polidocanol. Gas formulations studied included RA, CO2
and mixtures of carbon dioxide and oxygen (CO2:O2). The
volume ratio between liquid and gas was varied in a range
of clinical interest [26–29], from 1:4 (wet foams) to 1:7
(dry foams).
Two methods of PCF production were investigated in
the present study: (i) DSS and (ii) Tessari [30].
In the DSS method, foam was produced by passing the
polidocanol solution from a 5 mL syringe, ten times into
and out of a 10 mL syringe. Syringes were purchased from
BD Biosciences (USA) and were connected via a Combi-
dynTM adapter (B. Braun Melsungen, Germany) (Fig. 3a)
[30]. In the Tessari method, the straight connector was
replaced with a three-way valve which was set at a 30 off-
set (Fig. 3b) [30]. Experiments were conducted at room
temperature (*23 C), after foam production, and foams
were produced by the same operator.
Polidocanol endovenous microfoam (PEM) Varithena
(polidocanol injectable foam) 1 % (denoted as PEM for
brevity) is a combination drug device product manufac-
tured by Provensis Ltd (a BTG International group com-
pany, London, UK) consisting of a proprietary 35:65
CO2:O2 gas mixture with ultralow nitrogen content
(\0.8 %) and 1 % polidocanol solution, contained within a
pressurised canister and combined on discharge from the
canister as a uniform microfoam. PEM has a fixed LGR of
1:7. Sterile canisters of the product were employed as per
the instructions for use (see Supplementaty Fig. S1).
Experiments were conducted at room temperature
(*23 C), after foam production, and foams were pro-
duced by the same operator.
2.2.2 Measuring foam injection and degradation dynamics
The biomimetic model was filled with a solution of glyc-
erol (Sigma Aldrich Co., USA) in purified water (Milli-Q,
Fig. 1 Schematic depiction of the experimental set-up (readapted
from Ref. [32]). The biomimetic vein model was initially primed with
a blood substitute. Subsequently, sclerosing foam was injected into
the model and videos of foam plug expansion and degradation were
recorded by a CCD camera. Videos were transferred to the
computational foam analysis system (CFAS) for determination of
foam plug degradation rate (DR) and dwell time (DT). A three-way
valve was used to manually switch between blood substitute and
foam. Fluids were discharged in a reservoir
Fig. 2 Generic chemical structure of polidocanol. It comprises a
mixture of polyethylene glycol monododecyl ethers, averaging nine
ethylene oxide groups per molecule
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Millipore Co., USA), acting as a blood substitute. The
volume concentration of glycerol in water was equal to
*30 %, leading to a dynamic viscosity (l) of*0.003 Pa s
and a density (q) of *1078 kg/m3 [31], simulating the
bulk physical properties of blood.
After production, the foam was injected into the model
where it formed a plug (see Supplementary Video 1 for a
representative experimental injection procedure). The
bolus of foam displaced the blood substitute as it travelled
upwards (foam plug expansion phase). However, the foam
plug was transient in nature and receded towards the initial
injection site (foam plug degradation phase), until com-
plete plug degradation (see Supplementary Video 1).
Foam dynamics were captured by the CCD camera, and
videos were transferred to a PC for analysis.
2.2.3 Computational foam analysis system
The computational foam analysis system (CFAS v1.0) has
been employed to quantify foam cohesiveness, as described
in our previous study [12]. Briefly, the software reads the
acquired videos and measures the temporal evolution of
foam plug length (L, in mm), during both the expansion
and degradation phases. Finally, it calculates the rate of
foam plug degradation [degradation rate (DR) in mm/s]
from linear interpolation of the experimental data points
during the plug degradation phase. Lower DR as a result of
greater foam cohesiveness was taken as an indicator of
better clinical performance. Dwell time (DT, in s/cm) is a
more clinically meaningful expression of degradation rate
as it represents the amount of time that the foam is in
contact with the vein wall and can act on the endothelium.
DT is derived from DR and is calculated as the inverse of
the DR. Supplementary Videos 1–3 show examples of
experimental foam plug expansion and degradation in the
biomimetic model for different foam formulations, and the
corresponding dynamic plot of foam plug length deter-
mined by CFAS. DR and DT were determined from this
plot, in an automated fashion.
2.2.4 Multi-parametric analysis of foam cohesiveness
The effect of clinically-relevant parameters on foam
cohesiveness was investigated using the biomimetic model.
These are summarised in Table 1, and include:
• Model diameter 4 and 10 mm ID tubing were employed
to simulate both small and large varicose veins.
• Foam production technique Foam was produced man-
ually (by DSS or Tessari method), or using PEM.
• Gaseous phase Gases investigated for PCF production
included RA, 100 % CO2, 65 %:35 % CO2:O2 and
35 %:65 % CO2:O2.
• Foam density Foam density was varied by adjusting the
percentage volume of liquid and gaseous phases. LGRs
investigated included 1:3, 1:4, 1:5, and 1:7.
• Time delay between foam preparation and injection in
the model Foam was injected within 3–5 s from
production (e.g. immediate injection) or 75 s from
production (e.g. delayed injection), to simulate differ-
ent clinical practises.
• Effect of injection speed Foam was injected into the
model at different speeds, and the effect on DT
determined.
Fig. 3 Manual techniques for
producing sclerosing foams. In
the double syringe system
(DSS) method syringes (BD
DiscarditTM II) were connected
by a Combidyn adapter (a),
while in the Tessari method they
were connected by a three-way
valve set at a 30 off-set (b). In
both production methods, the
foam was generated by passing
the polidocanol solution (liquid
phase) from one syringe, ten
times into and out of the other
syringe initially containing a gas
or gas mixture (gaseous phase).
Throughout these studies, foam
was produced at room
temperature by a single operator
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2.3 Measuring foam bubble size distribution
A QICPIC particle size and shape analyser (supplied by
Sympatec UK, Bury, Lancashire) was employed to mea-
sure bubble size distribution of different foam formulations
(see also Ref. [32] for additional information about this
measurement system).
For this purpose, a foam sample was loaded within a
10 mL capacity BD syringe and placed on a syringe pump
(Harvard Apparatus PHD/ULTRA, Holliston, MA). The
foam was injected at a rate of 37.6 mL/min into a stream of
deionised water (driven by a peristaltic pump, Watson
Marlow 505S, Falmouth, UK) that carried the bubbles
through a 2 mm cuvette within the particle analyser where
detection occurred. The detector was positioned at the
midpoint across the height of the cuvette. A built-in image
analysis software captured images of the flowing bubbles at
25 frames per second, and generated a plot of bubble size
distribution. Each analysis comprised of five replicates,
each consisting of 15 s long acquisition intervals. The time
taken from filling of the syringe with foam to beginning of
the analysis was *35–40 s.
3 Results
3.1 Effect of method and composition of foam
formulation
PCFs produced using the DSS method had longer DT in the
4 mm diameter vein model (range 0.54–2.21 s/cm) than
those of the corresponding PCFs produced by the Tessari
technique (range 0.29–0.94 s/cm) (Fig. 4a vs. b). There
was no obvious dependence of the LGR on the DT of any
of the PCFs produced using either technique. Foams made
using 100 % CO2 were less stable, with lower DT than the
other PCFs (see Supplementary Video S1). PEM had the
longest DT indicating the best cohesive stability of any of
the foams produced (DT = 2.92 s/cm), including those
PCFs generated using the equivalent LGR (1:7) (see Sup-
plementary Video S2 for a RA PCF, and Video S3 for
PEM).
3.2 Effect of biomimetic vein model variables
3.2.1 Influence of vessel diameter
All foams failed to form a stable foam plug that could
displace the blood substitute in the 10 mm diameter vessel,
when the angle of inclination was 25. The angle had to be
adjusted by trial and error down to 5 in order to permit the
least stable foam (100 % CO2 PCF) to create a plug in the
vessel for which the DT could be measured. All foam
Fig. 4 Dwell Times (in s/cm) for DSS PCFs (a) or Tessari PCFs
(b) of different gas formulations and LGRs compared to PEM, in the
4 mm diameter vein model. DSS Double syringe system, PCF
physician compounded foam, PEM polidocanol endovenous micro-
foam, LGR liquid to gas ratio
Table 1 Clinically-relevant parameters investigated in the present study, using the developed biomimetic model and computational foam
analysis system (CFAS). N = 4 for each experimental condition
Tube ID 4 mm 10 mm
Foam production technique DSS Tessari PEM
Gaseous phase RA 35:65 CO2:O2 65:35 CO2:O2 100 CO2
Liquid:Gas ratio (LGR) 1:3 1:4 1:5 1:7
Time delay before injection 3–5 s 75 s
Foam plug expansion rate (injection speed) In the range 20.9–52.1 mm/s
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formulations evaluated in the 10 mm diameter vein model
had DTs significantly higher than the equivalent formula-
tions used in the 4 mm diameter vein model (Fig. 5), as the
vein angle had been reduced. Again, PCFs generated using
the DSS method had longer DTs (range 5.3–29.3 s/cm)
than the equivalent formulations made using the Tessari
technique (range 3.71–9.73 s/cm). PCF foam performance
was in the order RA[CO2:O2 (35:65) % CO2:O2
(65:35)[CO2; PEM had a longer DT than all PCFs
(DT = 22.10 s/cm) except that for RA made by DSS
which was similar but more variable.
3.2.2 Influence of injection delay
PCFs with different gas formulations were manufactured
at a typical clinical LGR of 1:3 and also at 1:7 to allow
for direct comparison with PEM. Foams were evaluated
in the vein model with an intention to determine the
influence of injection delay on foam cohesiveness
(Fig. 6). CO2:O2 PCF formulations made with a LGR of
1:3 had longer DT compared to PCFs with a LGR of 1:7,
whereas the reverse was true for RA PCFs. These dif-
ferences between formulations were somewhat lost when
injection was delayed (i.e., 75 s from production) with all
foams having lower DT compared to those injected
immediately (i.e., 3–5 s from production). PEM had the
longest DT of all foams with the lowest percentage
deviation in DT with respect to the mean values, indi-
cating a consistent foam performance (Table 2), although
the PCF with CO2:O2 (35:65) was also reasonably con-
sistent when injected immediately, which has the same
gas mixture formulation as PEM.
3.2.3 Influence of rate of foam plug formation (injection
speed)
It was observed that it was necessary to inject the various
foam formulations into the vein model at different rates in
order to ensure a foam plug was formed that would dis-
place the blood substitute. This pseudo-injection speed
actually represents the rate of foam formation in the vessel
where it volumetrically expands to form a coherent plug.
The foam plug formation rate was determined computa-
tionally using the CFAS, and was calculated from the
gradient of the line interpolating the experimental foam
plug length (L) vs. time (t) data points (see Supplementary
Videos 1–3). Figure 7 shows a plot of the DT (normalised
to the highest DT in order to visualise all of the results
easily on the same graph) against the plug formation rate
required for each experiment, for a selection of PCFs
created using the DSS method and PEM. Firstly, it is clear
that for the unstable 100 % CO2-based foam formulations,
the DT is low regardless of the rate of plug expansion,
Fig. 5 Dwell Times (DT, in s/cm) generated using the 10 mm vein
model at 5 inclination angle for DSS PCFs or Tessari PCFs of
different gas formulations, compared to PEM. Foams were produced
at a fixed LGR = 1:7. DSS Double syringe system, PCF physician
compounded foam, PEM polidocanol endovenous microfoam, LGR
liquid to gas ratio
Fig. 6 Effect of immediate (3–5 s) versus delayed (75 s) injection on
the Dwell Time (DT, in s/cm) for DSS PCFs of different gas
formulations made at 1:3 (a) or 1:7 (b) LGRs compared to PEM. DSS
Double syringe system, PCF physician compounded foam, PEM
polidocanol endovenous microfoam, LGR liquid to gas ratio
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although rates of [50 mm/s were required in some
instances to form a suitable foam plug (mean formation
rate = 43.7 mm/s). There appears to be no obvious cor-
relation between DT and rate of plug formation for any of
the foams (mean formation rate = 35.5 mm/s for RA and
37.7 mm/s for 35:65 CO2:O2) but what is clear is that PEM
consistently produces the longest DT, and this is possible
even at low plug formation rates (mean formation
rate = 29.5 mm/s). The stability and cohesive properties of
the PEM mean that a foam plug can be formed even if the
foam is injected relatively slowly (as low as 20.9 mm/s in
this series of experiments), whereas for PCFs slow injec-
tion will tend to lead to bubble streaming from the leading
edge of the foam hindering complete plug formation.
3.2.4 Bubble size and size distribution
Figure 8 shows bubble size distribution (expressed in terms
of volume fraction) of (a) DSS PCFs versus PEM (at a
fixed LGR = 1:7) and (b) DSS RA versus Tessari RA.
These were measured using the Sympatec particle size
analyser, at 35–40 s after foam production.
PCF produced using 100 % CO2 had the broadest bub-
ble size distribution, with large bubbles (500 lm in
diameter) present (see inset in Fig. 8a for a clear view).
PCFs produced using mixtures of CO2 and O2 had a nar-
rower bubble size distribution, but bubbles larger than
500 lm in diameter still persisted in the bubble population.
Notably, PEM had a narrower bubble size distribution
compared to PCFs with analogous composition, with no
large bubbles (i.e., bubble diameter was \*500 lm)
Fig. 7 Plot of normalised dwell time (DT) versus Plug Formation
Rate (in mm/s) for various PCF formulations (DSS) compared to
PEM (foams were injected immediately after production). DSS
Double syringe system, PCF physician compounded foam, PEM
polidocanol endovenous microfoam, LGR liquid to gas ratio
Table 2 Variability in dwell
time (DT) from different foam
formulations, expressed as
percentage deviation of the
mean
% Deviation of the mean DT 1:3 LGR % Deviation of the mean DT 1:7 LGR
Immediate injection Delayed injection Immediate injection Delayed injection
RA 24.3 32.2 29.6 20.0
35:65 CO2:O2 5.5 23.1 14.6 31.3
65:35 CO2:O2 16.7 35.6 35.9 26.5
100 CO2 11.8 19.5 24.0 11.8
PEM 8.5 2.2 8.5 2.2
Fig. 8 a Bubble size distributions (expressed in terms of volume
fraction) of DSS PCFs and PEM, obtained using the Sympatec
particle size analyser, at a fixed LGR = 1:7 (n = 5). The inset shows
an expanded view of bubble size distribution for bubble diameters
ranging from 550 to 1550 lm. b Bubble size distributions of RA DSS
versus RA Tessari, at a fixed LGR = 1:7 (n = 5). All measurements
in (a) and (b) were performed 35–40 s after foam production. DSS
Double syringe system, PCF physician compounded foam, PEM
polidocanol endovenous microfoam, LGR liquid to gas ratio
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which was comparable to RA PCFs (Fig. 8a). The Tessari
method produced bubbles which were larger and more
polydisperse in size compared to DSS with equivalent
composition, as clearly visible from Fig. 8b for RA
foams.
4 Discussion
When considering the general experimental observations
made during this series of studies, it can be seen that PCFs
generated using the DSS technique were more stable and
produced longer DT in the vein model compared to the
same PCFs made by the Tessari method. We have observed
this effect before, and have attributed this to the broader
bubble size distribution in Tessari PCFs compared to DSS
PCFs [32] (Fig. 8). Notably, it has been previously repor-
ted that (i) a more uniform bubble size distribution is
associated with more stable foams [33, 34], as differences
in Laplace pressure among bubbles of different size drive
transfer of gas from the smaller to the larger bubbles
through the liquid separating them (a process known as
disproportionation or Ostwald ripening [35, 36]). This
process is further enhanced when the amount of separating
liquid reduces [21]. (ii) Foams with smaller bubbles have
greater stability, which has been attributed to reduced liq-
uid drainage [37].
CO2-containing PCFs are also less stable compared to
RA PCFs as they contain a high fraction of a very aqueous-
soluble gas (CO2) compared to the low solubility of
nitrogen contained in RA; foam degradation is therefore
further promoted by the solubilisation of the gas phase into
the liquid phase between the bubbles due to a high rate of
interfacial mass transfer [38].
Furthermore, foam stability and bubble size distribution
have a significant effect on foam rheological properties,
and thus on its flow behaviour during injection [39].
In virtually every experiment performed, PEM produced
either the longest DT or was similar to that of most
stable PCFs generated using RA, indicating the best
cohesive stability in the model and slower rate of degra-
dation. The combination of the specific gas formulation and
more importantly, the low mean bubble size (no bubbles
greater than *500 lm in diameter upon foam generation)
and narrow bubble size distribution (see inset in Fig. 8a)
[32] resulted in a lower rate of Ostwald ripening. In terms
of clinical significance, the longer the foam DT in the
vessel, the more contact time the polidocanol surfactant has
with the endothelial lining of the vessel wall.
It has been demonstrated that the efficacy of the scle-
rosant is increased when the liquid sclerosant is formulated
into a foam [40]. As a liquid solution introduced into the
bloodstream, the sclerosant becomes diluted in the blood
volume and contact with the vessel wall is limited. When in
foam form, the sclerosant is present at the bubble interface
at high surface area and the foam can fill the vessel lumen,
displacing the blood volume and contacting the vessel
lining more efficiently with lower concentrations of scle-
rosant required. A balance of stability is required however,
in order that the foam does not break down before it can
efficiently fill the vein but also that it will degrade soon
after, and the component gases be absorbed into the
bloodstream. This ensures bubbles do not persist and travel
within the circulation where there is potential for them to
become lodged to form gas emboli in small vessels in the
brain. PEM offers an optimal balance of the cohesive sta-
bility characteristics of a nitrogen-containing foam pro-
viding for efficient vessel filling and piston effect to
displace blood, coupled with bioabsorbable gas formula-
tion in which the CO2 can dissolve in the blood and O2
sequestered by circulating haemoglobin.
Extrapolation of the results of our experiments to the
clinical situation would suggest that if treating patients
with larger varicosities, it may be of advantage to elevate
the leg to a less extreme angle in order for the foam to more
efficiently fill the vein and enable foam plug formation.
Our model would also predict that the foam should be
injected into the vein soon after it is formed, as all foams
undergo some degree of degradation over time which will
diminish their performance. The rate of injection is
important, as we have seen that PCFs tend to require a
faster rate of injection in order to ensure efficient foam plug
formation in the vessel (0.45–0.55 mL foam/s or 9–11 s for
a 5 mL foam injection). The administration of PEM is
insensitive to this however, as foams with long DTs have
been shown to be produced even when the rate of plug
formation is low (0.26 mL foam/s or 19.2 s for a 5 mL
foam injection). The use of PEM therefore has the
advantage of consistency, reducing some of the inherent
variability that arises from the use of PCF techniques.
5 Conclusions
The biomimetic vein model has been shown to be useful
for evaluating different foam formulations in terms of their
cohesive stability and potential usefulness for varicose vein
sclerotherapy. Stability of PCFs is affected by their method
of manufacture, gas composition and liquid to gas ratio.
CO2-containing foams have the advantage of gas solubility
to aid in foam absorption in the bloodstream but are less
stable and have shorter DTs in the vessel; a factor likely to
affect the efficacy of the foam. The PEM device produces a
foam that has the benefits of both a low-nitrogen gas for-
mulation and enhanced foam stability for longer DT in the
vein.
258 Page 8 of 10 J Mater Sci: Mater Med (2015) 26:258
123
6 Limitations and future work
There were some experimental limitations associated with
this study. These are outlined below, and may represent the
subject for future investigations:
• The stability of a foam plug in a vessel is likely to
depend on the physical properties of the vessel,
including wettability of its inner surface and surfactant
adsorption to the surface. It likely that the PTFE vein
model employed in the present study does not replicate
those properties of veins. Future studies may be
conducted on a second-generation vein model replicat-
ing more closely the physical and chemical properties
of blood vessels.
• Experiments in this study have been conducted using a
blood substitute (i.e., solution of glycerol in purified
water). However, it has been shown that biological
fluids (i.e., blood) have deactivation effects on scle-
rosants [41]. Therefore, further experiments should be
performed to investigate the effect of the bio-physical
properties of carrier fluids on the cohesiveness of
sclerosing foams.
• Polidocanol was employed as a detergent sclerosant
throughout these studies. However, a range of different
sclerosing agents is available for application in foam
sclerotherapy, and it is envisaged that different scle-
rosants (i.e., such as sodium tetradecyl sulphate or
alcohol) may be investigated with our model in the
future.
Acknowledgments In memory of our colleague Vincent O’Byrne
without whom these studies and many others would not have been
possible. We will dearly miss his infectious enthusiasm, positive
energy and sense of humour.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Bradbury A, Evans C, Allan P, Lee A, Vaughan Ruckley C,
Fowkes F. What are the symptoms of varicose veins? Edinburgh
vein study cross sectional population survey. BMJ.
1999;318(7180):353–6.
2. Goldman MP, Fronek A. Anatomy and pathophysiology of
varicose veins. J Dermatol Surg Oncol. 1989;15(2):138–46.
3. Van den Oever R, Hepp B, Debbaut B, Simon I. Socio-economic
impact of chronic venous insufficiency: an underestimated public
health problem. Int Angiol. 1998;17(3):161–7.
4. Murad MH, Coto-Yglesias F, Zumaeta-Garcia M, Elamin MB,
Duggirala MK, Erwin PJ, et al. A systematic review and meta-
analysis of the treatments of varicose veins. J Vasc Surg.
2011;53(5):49S–65S.
5. Smith PC. Foam and liquid sclerotherapy for varicose veins.
Phlebology. 2009;24(suppl 1):62–72.
6. Gibson K, Regan J, Shortell C. Proprietary polidocanol endove-
nous microfoam (PEM) bubble embolization does not cause
cerebral injury. Phlebology. 2009;24:85.
7. Watkins M. Deactivation of sodium tetradecyl sulphate injection
by blood proteins. Eur J Vasc Endovasc Surg. 2011;41(4):521–5.
8. Hsu T-S, Weiss RA. Foam sclerotherapy: a new era. Arch Der-
matol. 2003;139(11):1494–6.
9. Rao J, Goldman MP. Stability of foam in sclerotherapy: differ-
ences between sodium tetradecyl sulfate and polidocanol and the
type of connector used in the double-syringe system technique.
Dermatol Surg. 2005;31(1):19–22.
10. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a
new sclerosing foam in the treatment of varicose veins. Dermatol
Surg. 2001;27(1):58–60.
11. Peterson JD, Goldman MP. An investigation into the influence of
various gases and concentrations of sclerosants on foam stability.
Dermatol Surg. 2011;37(1):12–7.
12. Carugo D, Ankrett DN, O’Byrne V, Willis S, Wright DD, Lewis
AL, et al. A novel biomimetic analysis system for quantitative
characterisation of sclerosing foams used for the treatment of
varicose veins. J Mater Sci. 2013;24:1–7.
13. Coleridge Smith P. Sclerotherapy and foam sclerotherapy for
varicose veins. Phlebology. 2009;24(6):260–9.
14. Eckmann DM, Kobayashi S, Li M. Microvascular embolization
following polidocanol microfoam sclerosant administration.
Dermatol Surg. 2005;31(6):636–43.
15. Morrison N, Neuhardt DL, Rogers CR, McEown J, Morrison T,
Johnson E, et al. Comparisons of side effects using air and carbon
dioxide foam for endovenous chemical ablation. J Vasc Surg.
2008;47(4):830–6.
16. Morrison N, Neuhardt DL, Rogers CR, McEown J, Morrison
T, Johnson E, et al. Incidence of side effects using carbon
dioxide-oxygen foam for chemical ablation of superficial
veins of the lower extremity. Eur J Vasc Endovasc Surg.
2010;40(3):407–13.
17. Douglas AR, Jones NL, Reed JW. Calculation of whole blood
CO2 content. J Appl Physiol. 1988;65(1):473–7.
18. Guex J-J. Foam sclerotherapy: an overview of use for primary
venous insufficiency. Semin Vasc Surg. 2005;18(1):25–9.
19. Eckmann DM. Polidocanol for endovenous microfoam sclerosant
therapy. Expert Opin Investig Drugs. 2009;18(12):1919–27.
20. Cavezzi A, Tessari L. Foam sclerotherapy techniques: different
gases and methods of preparation, catheter versus direct injection.
Phlebology. 2009;24(6):247–51.
21. Van Deurzen B, Ceulen RP, Tellings SS, Van der Geld C, Nijsten
T. Polidocanol concentration and time affect the properties of
foam used for sclerotherapy. Dermatol Surg. 2011;37(10):
1448–55.
22. Nastasa V, Samaras K, Ampatzidis C, Karapantsios T, Trelles M,
Moreno-Moraga J, et al. Properties of polidocanol foam in view
of its use in sclerotherapy. Int J Pharm. 2015;478(2):588–96.
23. Wong K, Chen T, Connor DE, Behnia M, Parsi K. Basic
physiochemical and rheological properties of detergent
sclerosants. Phlebology. 2014;. doi:10.1177/026835
5514529271.
24. Hamel-Desnos C, Ouvry P, Desnos P, Allaert F. Mousse de
polidocanol 3 versus 1% dans la scle´rothe´rapie de la grande veine
saphe`ne. E´tude randomise´e en double insu avec suivi sur deux
ans. Phle´bologie. 2008;61(1):103–9.
J Mater Sci: Mater Med (2015) 26:258 Page 9 of 10 258
123
25. Ceulen RP, Yi B-G, Sj P-VDV, Nelemans PJ, Veraart JC,
Sommer A. Outcomes and side effects of duplex-guided scle-
rotherapy in the treatment of great saphenous veins with 1%
versus 3% polidocanol foam: results of a randomized controlled
trial with 1-year follow-up. Dermatol Surg. 2007;33(3):276–81.
26. Hamel-Desnos C, Desnos P, Wollmann JC, Ouvry P, Mako S,
Allaert FA. Evaluation of the efficacy of polidocanol in the form
of foam compared with liquid form in sclerotherapy of the greater
saphenous vein: initial results. Dermatol Surg. 2003;29(12):
1170–5.
27. Jia X, Mowatt G, Burr J, Cassar K, Cook J, Fraser C. Systematic
review of foam sclerotherapy for varicose veins. Br J Surg.
2007;94(8):925–36.
28. Blaise S, Bosson J, Diamand J. Ultrasound-guided sclerotherapy
of the great saphenous vein with 1% vs. 3% polidocanol foam: a
multicentre double-blind randomised trial with 3-year follow-up.
Eur J Vasc Endovasc Surg. 2010;39(6):779–86.
29. Rabe E, Pannier F. Sclerotherapy of varicose veins with polido-
canol based on the guidelines of the German Society of Phle-
bology. Dermatol Surg. 2010;36(s2):968–75.
30. Wollmann JCG. The history of sclerosing foams. Dermatol Surg.
2004;30(5):694–703.
31. Segur JB, Oberstar HE. Viscosity of glycerol and its aqueous
solutions. Ind Eng Chem. 1951;43(9):2117–20.
32. Carugo D, Ankrett DN, Zhao X, Zhang X, Hill M, O’Byrne V,
et al. Benefits of polidocanol endovenous microfoam
(Varithena) compared with physician-compounded foams.
Phlebology. 2015;. doi:10.1177/0268355515589063.
33. Sarma DSR, Khilar KC. Effects of initial gas volume fraction on
stability of aqueous air foams. Ind Eng Chem Res. 1988;27(5):
892–4.
34. Monsalve A, Schechter RS. The stability of foams: dependence of
observation on the bubble size distribution. J Colloid Interface
Sci. 1984;97(2):327–35.
35. Małysa K. Wet foams: formation, properties and mechanism of
stability. Adv Colloid Interface Sci. 1992;40:37–83.
36. Maurdev G, Saint-Jalmes A, Langevin D. Bubble motion mea-
surements during foam drainage and coarsening. J Colloid
Interface Sci. 2006;300(2):735–43.
37. Rand PB, Kraynik AM. Drainage of aqueous foams: generation-
pressure and cell-size effects. Soc Pet Eng J. 1983;23(01):152–4.
38. Hanwright J, Zhou J, Evans GM, Galvin KP. Influence of sur-
factant on gas bubble stability. Langmuir. 2005;21(11):4912–20.
39. Calvert J, Nezhati K. Bubble size effects in foams. Int J Heat
Fluid Flow. 1987;8(2):102–6.
40. Ouvry P, Allaert F-A, Desnos P, Hamel-Desnos C. Efficacy of
polidocanol foam versus liquid in sclerotherapy of the great
saphenous vein: a multicentre randomised controlled trial with a
2-year follow-up. Eur J Vasc Endovasc Surg. 2008;36(3):366–70.
41. Connor D, Cooley-Andrade O, Goh W, Ma D, Parsi K. Detergent
sclerosants are deactivated and consumed by circulating blood
cells. Eur J Vasc Endovasc Surg. 2015;49(4):426–31.
258 Page 10 of 10 J Mater Sci: Mater Med (2015) 26:258
123
